Cefizox IN dextrose 5% IN plastic container

Base Information

• Chemical Name: Cefizox IN dextrose 5% IN plastic container
• CAS No.: 68401-82-1
• Molecular Formula: C13H12N5NaO5S2
• Molecular Weight: 405.39
• Hs Code.: 2941905990
• European Community (EC) Number: 629-729-8
• NCI Thesaurus Code: C47438
• Mol file: 68401-82-1.mol

Synonyms:Cefizox;Ceftizoxime;Ceftizoxime Monosodium Salt;Ceftizoxime Sodium;FK 749;FK-749;FK749;FR 13749;FR-13749;FR13749;Monosodium Salt, Ceftizoxime;Salt, Ceftizoxime Monosodium;SK and F 88373 2;SK and F 88373-2;SK and F 883732;SKF 88373;SKF-88373;SKF88373;Sodium, Ceftizoxime

Chemical Property of Cefizox IN dextrose 5% IN plastic container

Chemical Property:

• Appearance/Colour: White to light yellow crystalline powder
• Melting Point: 227℃
• PSA: 203.58000
• LogP: -0.98050
• Storage Temp.: -20°C
• Solubility.: DMSO: soluble1mg/mL
• Water Solubility.: Soluble in water
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 10
• Rotatable Bond Count: 5
• Exact Mass: 405.01775513
• Heavy Atom Count: 26
• Complexity: 675

Purity/Quality:

99% ^*data from raw suppliers

Ceftizoxime sodium salt ≥98% (HPLC) ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xi
• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: CON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=CCS3)C(=O)[O-].[Na+]
• Recent NIPH Clinical Trials: A multicenter, open-label, single-dose study to investigate the effects of the ABCC4 (MRP4) rs3765534 G>A polymorphism on the pharmacokinetics of ceftizoxime in East Asian population
• Uses: A broad spectrum antibiotic targeting a wide variety of Gram-positive and Gram-negative bacteria Antibacterial.
• Therapeutic Function: Antibacterial
• Clinical Use: Ceftizoxime (Cefizox) is a third-generation cephalosporinthat was introduced in 1984. This β-lactamase–resistant agentexhibits excellent activity against the Enterobacteriaceae,especially E. coli, K. pneumoniae, E. cloacae, Enterobacteraerogenes, indole-positive and indole-negative Proteus spp.,and S. marcescens. Ceftizoxime is claimed to be more activethan cefoxitin against B. fragilis. It is also very active againstGram-positive bacteria. Its activity against P. aeruginosa issomewhat variable and lower than that of either cefotaxime orcefoperazone.Ceftizoxime is not metabolized in vivo. It is excretedlargely unchanged in the urine. Adequate levels of the drugare achieved in the cerebrospinal fluid for the treatment ofGram-negative or Gram-positive bacterial meningitis. It mustbe administered on a thrice-daily dosing schedule because ofits relatively short half-life. Ceftizoxime sodium is very stablein the dry state. Solutions maintain potency for up to 24hours at room temperature and 10 days when refrigerated.